As seasonal flu activity continues to rise across Europe, the United States, Africa, and Southeast Asia, fast and reliable diagnostic solutions are in high demand. BABIO (Babio Biotechnology), a leading Chinese manufacturer of rapid diagnostic test kits, has introduced its Influenza A/B Antigen Detection Kit (Colloidal Gold Method) to support timely detection and better clinical decision-making worldwide.

The kit uses a high-sensitivity lateral flow immunoassay to detect Influenza A and Influenza B antigens from nasal or throat specimens within minutes. Designed with dual test lines (T1 for Flu A, T2 for Flu B) and a built-in quality control line, the device ensures accurate, easy-to-interpret results suitable for hospitals, clinics, emergency screening points, airports, and community healthcare programs.

With influenza outbreaks becoming increasingly unpredictable, healthcare providers require dependable tools that deliver rapid answers. BABIO’s test kit is engineered for quick screening, early isolation, and efficient clinical management, making it an ideal solution for regions with rising flu cases.

BABIO continues to expand its global presence as one of China’s most recognized producers of high-quality diagnostic reagents and rapid tests.
For more product details, certifications, or distribution opportunities, please visit the official website: https://www.babiomed.com

#InfluenzaTest #FluABTest #RapidAntigenTest #BABIO #RespiratoryDiagnostics #PointOfCareTesting #ColloidalGoldTest #GlobalHealth #MedicalDevices #InfectiousDiseaseTesting